Navigation Links
BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients.

The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan® (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell lymphocytes can undergo malignant transformation to become non-Hogkins
'"/>

Source:The Investor Relations Group


Page: 1 2

Related biology news :

1. Hunger in America rises by 43 percent over last five years
2. Method slashes quantum dot costs by 80 percent
3. Hepatitis B accounts for 40 percent of missing Asian women
4. Vaccine provides 100 percent protection against avian flu virus in animal study
5. Oceans are 70 percent shark free
6. St. Jude projects 90 percent cure rate for ALL
7. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
8. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
9. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
10. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
11. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
Post Your Comments:
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... a chronic swelling condition that can appear after ... million breast cancer survivors. Although lymphedema can cause ... chest, there is no national standard of diagnosis ... leading the American Lymphedema Framework Project (ALFP), a ...
... On the first anniversary of the American Recovery ... the nation,s research universities today provided nearly 100 examples ... is paying outsize short- and long-term dividends for the ... ARRA, $21.5 billion is allocated for research and science ...
... State University graduate students teaching introductory biology labs are ... engage their students in critical thinking, and even craft ... a Graduate Teacher Training Program supported by a portion ... university has received. The training program is operated by ...
Cached Biology News:Researchers develop standard of care for breast cancer survivors with lymphedema 2Universities highlight benefits of stimulus research funding 2Universities highlight benefits of stimulus research funding 3Oregon State trains graduate students to be better TAs 2Oregon State trains graduate students to be better TAs 3Oregon State trains graduate students to be better TAs 4
(Date:4/20/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... one of its proprietary human-derived CPP sequences and a ... of NFkB signalling even if administered when the BBB ... blood brain barrier (BBB) in mice was studied and ...
(Date:4/20/2015)... 20, 2015   Meditope Biosciences, Inc ., a ... technology, today announced presentation of data demonstrating the use ... antibody-drug conjugates (ADCs). The data were presented in an abstract ... 18-22 in Philadelphia . ... point to the many commercial applications that may be ...
(Date:4/20/2015)... 2015 Whitehouse Laboratories is pleased and ... most recent Food and Drug Administration (FDA) inspection and ... five day, GMP compliance inspection, as based upon 21CFR ... through April 6th and was granted NAI (no action ... the strict Good Manufacturing Practice (GMP) quality system required ...
(Date:4/17/2015)... April 17, 2015  Centrillion Technologies, a ... grant from the National Human Genome Research ... Health (NIH). The grant will help fund ... development of breakthrough genomic technologies, including phased ... substrates. Centrillion has been developing this transformative ...
Breaking Biology Technology:Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3
... NEW YORK, Feb. 4 Emisphere Technologies, Inc.,(Nasdaq: ... unique and,improved delivery of therapeutic molecules using its eligen(R) ... BIO CEO & Investor,Conference on February 12, 2008 at ... V. Novinski, President and Chief Executive Officer of,Emisphere, will ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, California, ... through its wholly owned subsidiary Jade,Pharmaceutical Inc. ... with Jade, engages in the development, manufacture ... diagnostic products. The,Company announced today that JPI,s ...
... - Conference Call Scheduled for 5 February 2008, 09:00 ... ... BRISBANE, Australia, Feb. 4 Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... to acquire privately-held U.S.,oncology company CellGate, Inc. The CellGate acquisition ...
Cached Biology Technology:Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12 2AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities 2Progen Expands Drug Development Pipeline Through Acquisition of CellGate 2Progen Expands Drug Development Pipeline Through Acquisition of CellGate 3Progen Expands Drug Development Pipeline Through Acquisition of CellGate 4Progen Expands Drug Development Pipeline Through Acquisition of CellGate 5
Human PLUNC MAb (Clone 252512)...
... to GRASP1 ( Abpromise for ... Antigen: Synthetic peptide corresponding to ... terminal region of rat GRASP1, conjugated ... Entrez GeneID: 56850 ...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Biology Products: